Plasma metabolomics in adults with cystic fibrosis during a pulmonary exacerbation: A pilot randomized study of high-dose vitamin D3 administration.

BACKGROUND Cystic fibrosis (CF) is a chronic catabolic disease often requiring hospitalization for acute episodes of worsening pulmonary exacerbations. Limited data suggest that vitamin D may have beneficial clinical effects, but the impact of vitamin D on systemic metabolism in this setting is unknown. OBJECTIVE We used high-resolution metabolomics (HRM) to assess the impact of baseline vitamin D status and high-dose vitamin D3 administration on systemic metabolism in adults with CF with an acute pulmonary exacerbation. DESIGN Twenty-five hospitalized adults with CF were enrolled in a randomized trial of high-dose vitamin D3 (250,000IU vitamin D3 bolus) versus placebo. Age-matched healthy subjects served as a reference group for baseline comparisons. Plasma was analyzed with liquid chromatography/ultra-high resolution mass spectrometry. Using recent HRM bioinformatics and metabolic pathway enrichment methods, we examined associations with baseline vitamin D status (sufficient vs. deficient per serum 25-hydroxyvitamin D concentrations) and the 7-day response to vitamin D3 supplementation. RESULTS Several amino acids and lipid metabolites differed between CF and healthy control subjects, indicative of an overall catabolic state. In CF subjects, 343 metabolites differed (P<0.05) by baseline vitamin D status and were enriched within 7 metabolic pathways including fatty acid, amino acid, and carbohydrate metabolism. A total of 316 metabolites, which showed enrichment for 15 metabolic pathways-predominantly representing amino acid pathways-differed between the vitamin D3- and placebo-treated CF subjects over time (P<0.05). In the placebo group, several tricarboxylic acid cycle intermediates increased while several amino acid-related metabolites decreased; in contrast, little change in these metabolites occurred with vitamin D3 treatment. CONCLUSIONS Numerous metabolic pathways detected by HRM varied in association with vitamin D status and high-dose vitamin D3 supplementation in adults with CF experiencing a pulmonary exacerbation. Overall, these pilot data suggest an anti-catabolic effect of high-dose vitamin D3 in this clinical setting.

[1]  Reshma Shah,et al.  Vitamin D and bone health in adults with cystic fibrosis , 2008, Clinical endocrinology.

[2]  Karan Uppal,et al.  Reference Standardization for Mass Spectrometry and High-resolution Metabolomics Applications to Exposome Research. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  Dean P. Jones,et al.  High-Resolution Metabolomics for Nutrition and Health Assessment of Armed Forces Personnel , 2016, Journal of occupational and environmental medicine.

[4]  K. Carson,et al.  Current treatment recommendations for correcting vitamin D deficiency in pediatric patients with cystic fibrosis are inadequate. , 2008, The Journal of pediatrics.

[5]  Catherine A Rimmer,et al.  Development of a Standard Reference Material for metabolomics research. , 2013, Analytical chemistry.

[6]  A. Lindblad,et al.  Vitamin D deficiency as a risk factor for cystic fibrosis-related diabetes in the Scandinavian Cystic Fibrosis Nutritional Study , 2011, Diabetologia.

[7]  K. O’Brien,et al.  Vitamin D Status Affects Serum Metabolomic Profiles in Pregnant Adolescents , 2013, Reproductive Sciences.

[8]  L. Brennan,et al.  Metabolic Profiling of Human Peripheral Blood Mononuclear Cells: Influence of Vitamin D Status and Gender , 2014, Metabolites.

[9]  P. Davis,et al.  Epidemiology of Cystic Fibrosis. , 2016, Clinics in chest medicine.

[10]  P. Dhawan,et al.  Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. , 2016, Physiological reviews.

[11]  J. Binongo,et al.  The effect of a single, large bolus of vitamin D in healthy adults over the winter and following year: a randomized, double-blind, placebo-controlled trial , 2014, European Journal of Clinical Nutrition.

[12]  Dean P. Jones,et al.  Metabolic Characterization of the Common Marmoset (Callithrix jacchus) , 2015, PloS one.

[13]  Tianwei Yu,et al.  xMSanalyzer: automated pipeline for improved feature detection and downstream analysis of large-scale, non-targeted metabolomics data , 2013, BMC Bioinformatics.

[14]  N. Deutz,et al.  Protein is an important but undervalued macronutrient in the nutritional care of patients with cystic fibrosis , 2014, Current opinion in clinical nutrition and metabolic care.

[15]  R. Ghidoni,et al.  Role of Sphingolipids in the Pathobiology of Lung Inflammation , 2015, Mediators of inflammation.

[16]  L. Brennan,et al.  Biochemical and metabolomic phenotyping in the identification of a vitamin D responsive metabotype for markers of the metabolic syndrome. , 2011, Molecular nutrition & food research.

[17]  M. Fontana,et al.  The protective effect of hypotaurine and cysteine sulphinic acid on peroxynitrite-mediated oxidative reactions , 2008, Free radical research.

[18]  C. Carlberg,et al.  Epigenome-wide effects of vitamin D and their impact on the transcriptome of human monocytes involve CTCF , 2015, Nucleic acids research.

[19]  Bowerman,et al.  Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis , 2000, European journal of clinical investigation.

[20]  A. Moran,et al.  Vitamin D deficiency is associated with pulmonary exacerbations in children with cystic fibrosis. , 2014, Annals of the American Thoracic Society.

[21]  M. E. Shaker,et al.  Therapeutic Opportunities in Damage-Associated Molecular Pattern-Driven Metabolic Diseases. , 2015, Antioxidants & redox signaling.

[22]  G. Sawicki,et al.  Vitamin D status in children with cystic fibrosis. Associations with inflammation and bacterial colonization. , 2014, Annals of the American Thoracic Society.

[23]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[24]  R. Lyles,et al.  Impact of vitamin D supplementation on markers of inflammation in adults with cystic fibrosis hospitalized for a pulmonary exacerbation , 2012, European Journal of Clinical Nutrition.

[25]  George E Karniadakis,et al.  Omics, big data and machine learning as tools to propel understanding of biological mechanisms and to discover novel diagnostics and therapeutics. , 2018, Metabolism: clinical and experimental.

[26]  John H. White,et al.  Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. , 2005, Molecular endocrinology.

[27]  E. Levy,et al.  Cystic fibrosis-related oxidative stress and intestinal lipid disorders. , 2015, Antioxidants & redox signaling.

[28]  David S. Wishart,et al.  HMDB 3.0—The Human Metabolome Database in 2013 , 2012, Nucleic Acids Res..

[29]  D. Albanes,et al.  Metabolomics analysis of serum 25-hydroxy-vitamin D in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. , 2016, International journal of epidemiology.

[30]  Shuzhao Li,et al.  Computational Metabolomics: A Framework for the Million Metabolome , 2022 .

[31]  E. Kerem,et al.  Patients with cystic fibrosis and normoglycemia exhibit diabetic glucose tolerance during pulmonary exacerbation. , 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[32]  J. Jais,et al.  A Novel Lipidomic Strategy Reveals Plasma Phospholipid Signatures Associated with Respiratory Disease Severity in Cystic Fibrosis Patients , 2009, PloS one.

[33]  P. Dalcin,et al.  Hypovitaminosis D in patients with cystic fibrosis: a cross‐section study in South Brazil , 2014, The clinical respiratory journal.

[34]  Tianwei Yu,et al.  apLCMS - adaptive processing of high-resolution LC/MS data , 2009, Bioinform..

[35]  A. Lindblad,et al.  Inverse relation between vitamin D and serum total immunoglobulin G in the Scandinavian Cystic Fibrosis Nutritional Study , 2011, European Journal of Clinical Nutrition.

[36]  M. Mascarenhas,et al.  Nutritional Issues in Cystic Fibrosis. , 2016, Clinics in chest medicine.

[37]  Karan Uppal,et al.  Plasma Metabolomics in Human Pulmonary Tuberculosis Disease: A Pilot Study , 2014, PloS one.

[38]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[39]  M. Kumari,et al.  Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation , 2012, Dermato-endocrinology.

[40]  P. Galan,et al.  Prevalence of Vitamin D Insufficiency in an Adult Normal Population , 1997, Osteoporosis International.

[41]  W. Bernhard,et al.  Plasma Phosphatidylcholine Alterations in Cystic Fibrosis Patients: Impaired Metabolism and Correlation with Lung Function and Inflammation , 2015, Cellular Physiology and Biochemistry.

[42]  H. Quinton,et al.  Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. , 2008, Journal of the American Dietetic Association.

[43]  Shane P. Stenner,et al.  Appropriate goal level for 25-hydroxyvitamin D in cystic fibrosis. , 2011, Chest.

[44]  Shuzhao Li,et al.  Predicting Network Activity from High Throughput Metabolomics , 2013, PLoS Comput. Biol..

[45]  F. Ratjen,et al.  Decreased systemic bioavailability of L-arginine in patients with cystic fibrosis , 2006, Respiratory research.

[46]  Dean P. Jones,et al.  High-performance metabolic profiling with dual chromatography-Fourier-transform mass spectrometry (DC-FTMS) for study of the exposome , 2011, Metabolomics.

[47]  V. Tangpricha,et al.  Treatment of vitamin D deficiency in cystic fibrosis , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[48]  K. Robinson,et al.  An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. , 2012, The Journal of clinical endocrinology and metabolism.

[49]  S. Freedman,et al.  Gastrointestinal Disorders in Cystic Fibrosis. , 2016, Clinics in chest medicine.

[50]  Dean P. Jones,et al.  Endoplasmic reticulum stress in nonalcoholic fatty liver disease. , 2012, Annual review of nutrition.

[51]  C. Carlberg.  Genome-wide (over)view on the actions of vitamin D , 2014, Front. Physiol..